SM 101

Drug Profile

SM 101

Alternative Names: BAX 1810; FcγRIIb; Human soluble Fc-gamma receptor IIb - Shire; SHP 652; SM-101

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SuppreMol
  • Developer Baxalta; Shire
  • Class Immunoglobulin Fc fragments; Recombinant proteins
  • Mechanism of Action Fc gamma receptor IIB modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura; Systemic lupus erythematosus
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 02 Feb 2016 Baxalta withdraws a phase II trial for IgA nephropathy (Treatment-experienced) in USA (IV) (NCT02605525)
  • 19 Nov 2015 Baxalta plans a phase II trial for IgA nephropathy (Treatment-experienced) in USA (IV) (NCT02605525)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top